In the past week, PBM stock has gone up by 10.50%, with a monthly gain of 10.40% and a quarterly plunge of -64.77%. The volatility ratio for the week is 26.45%, and the volatility levels for the last 30 days are 17.26% for Psyence Biomedical Ltd The simple moving average for the past 20 days is 0.82% for PBM’s stock, with a -94.43% simple moving average for the past 200 days.
Is It Worth Investing in Psyence Biomedical Ltd (NASDAQ: PBM) Right Now?
PBM has 36-month beta value of -0.10.
The public float for PBM is 0.07M, and currently, short sellers hold a 34.16% ratio of that float. The average trading volume of PBM on May 09, 2025 was 37.48K shares.
PBM) stock’s latest price update
Psyence Biomedical Ltd (NASDAQ: PBM) has experienced a decline in its stock price by -9.36 compared to its previous closing price of 4.28. However, the company has seen a gain of 10.50% in its stock price over the last five trading days. newsfilecorp.com reported 2025-05-01 that New York, New York–(Newsfile Corp. – May 1, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company’s issued and outstanding common shares.
PBM Trading at -23.61% from the 50-Day Moving Average
After a stumble in the market that brought PBM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.45% of loss for the given period.
Volatility was left at 17.26%, however, over the last 30 days, the volatility rate increased by 26.45%, as shares surge +1.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.85% lower at present.
During the last 5 trading sessions, PBM rose by +10.09%, which changed the moving average for the period of 200-days by -98.35% in comparison to the 20-day moving average, which settled at $3.85. In addition, Psyence Biomedical Ltd saw -76.96% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PBM
The total capital return value is set at 0.5.
Based on Psyence Biomedical Ltd (PBM), the company’s capital structure generated 2.01 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at -1.99. The interest coverage ratio of the stock is -170.15.
Currently, EBITDA for the company is -2.75 million with net debt to EBITDA at -1.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.64.
Conclusion
To put it simply, Psyence Biomedical Ltd (PBM) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
